Cargando…
Antiseizure Medication-Induced Alopecia: A Literature Review
Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that has a high intolerance rate leading to poor therape...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301592/ https://www.ncbi.nlm.nih.gov/pubmed/37367730 http://dx.doi.org/10.3390/medicines10060035 |
_version_ | 1785064848715939840 |
---|---|
author | Pitton Rissardo, Jamir Fornari Caprara, Ana Leticia Casares, Maritsa Skinner, Holly J. Hamid, Umair |
author_facet | Pitton Rissardo, Jamir Fornari Caprara, Ana Leticia Casares, Maritsa Skinner, Holly J. Hamid, Umair |
author_sort | Pitton Rissardo, Jamir |
collection | PubMed |
description | Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that has a high intolerance rate leading to poor therapeutical compliance. Methods: We performed a literature review concerning alopecia as a secondary effect of ASMs. Results: There are 1656 individuals reported with ASM-induced alopecia. Valproate (983), lamotrigine (355), and carbamazepine (225) have been extensively reported. Other ASMs associated with alopecia were cenobamate (18), levetiracetam (14), topiramate (13), lacosamide (7), vigabatrin (6), phenobarbital (5), gabapentin (5), phenytoin (4), pregabalin (4), eslicarbazepine (3), brivaracetam (2), clobazam (2), perampanel (2), trimethadione (2), rufinamide (2), zonisamide (2), primidone (1), and tiagabine (1). There were no reports of oxcarbazepine and felbamate with drug-induced alopecia. Hair loss seen with ASMs was diffuse and non-scarring. Telogen effluvium was the most common cause of alopecia. A characteristic feature was the reversibility of alopecia after ASM dose adjustment. Conclusions: Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended. |
format | Online Article Text |
id | pubmed-10301592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103015922023-06-29 Antiseizure Medication-Induced Alopecia: A Literature Review Pitton Rissardo, Jamir Fornari Caprara, Ana Leticia Casares, Maritsa Skinner, Holly J. Hamid, Umair Medicines (Basel) Review Background: Adverse effects of antiseizure medications (ASMs) remain one of the major causes of non-adherence. Cosmetic side effects (CSEs) are among the most commonly reported side effects of ASMs. In this context, alopecia is one of the CSEs that has a high intolerance rate leading to poor therapeutical compliance. Methods: We performed a literature review concerning alopecia as a secondary effect of ASMs. Results: There are 1656 individuals reported with ASM-induced alopecia. Valproate (983), lamotrigine (355), and carbamazepine (225) have been extensively reported. Other ASMs associated with alopecia were cenobamate (18), levetiracetam (14), topiramate (13), lacosamide (7), vigabatrin (6), phenobarbital (5), gabapentin (5), phenytoin (4), pregabalin (4), eslicarbazepine (3), brivaracetam (2), clobazam (2), perampanel (2), trimethadione (2), rufinamide (2), zonisamide (2), primidone (1), and tiagabine (1). There were no reports of oxcarbazepine and felbamate with drug-induced alopecia. Hair loss seen with ASMs was diffuse and non-scarring. Telogen effluvium was the most common cause of alopecia. A characteristic feature was the reversibility of alopecia after ASM dose adjustment. Conclusions: Alopecia should be considered one important adverse effect of ASMs. Patients reporting hair loss with ASM therapy should be further investigated, and specialist consultation is recommended. MDPI 2023-06-09 /pmc/articles/PMC10301592/ /pubmed/37367730 http://dx.doi.org/10.3390/medicines10060035 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pitton Rissardo, Jamir Fornari Caprara, Ana Leticia Casares, Maritsa Skinner, Holly J. Hamid, Umair Antiseizure Medication-Induced Alopecia: A Literature Review |
title | Antiseizure Medication-Induced Alopecia: A Literature Review |
title_full | Antiseizure Medication-Induced Alopecia: A Literature Review |
title_fullStr | Antiseizure Medication-Induced Alopecia: A Literature Review |
title_full_unstemmed | Antiseizure Medication-Induced Alopecia: A Literature Review |
title_short | Antiseizure Medication-Induced Alopecia: A Literature Review |
title_sort | antiseizure medication-induced alopecia: a literature review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10301592/ https://www.ncbi.nlm.nih.gov/pubmed/37367730 http://dx.doi.org/10.3390/medicines10060035 |
work_keys_str_mv | AT pittonrissardojamir antiseizuremedicationinducedalopeciaaliteraturereview AT fornaricapraraanaleticia antiseizuremedicationinducedalopeciaaliteraturereview AT casaresmaritsa antiseizuremedicationinducedalopeciaaliteraturereview AT skinnerhollyj antiseizuremedicationinducedalopeciaaliteraturereview AT hamidumair antiseizuremedicationinducedalopeciaaliteraturereview |